Douglas C. Lane & Associates’s Novo Nordisk NVO Stock Holding History

Douglas C. Lane & Associates’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$19.9M	Sell	684,784 -32,322	-5%	-$895K	0.54%	69
2015 Q3	$19.4M	Sell	717,106 -1,898	-0.3%	-$53.7K	0.55%	69
2015 Q2	$19.7M	Sell	719,004 -21,838	-3%	-$614K	0.53%	71
2015 Q1	$19.8M	Buy	740,842 +112,470	+18%	+$2.59M	0.52%	72
2014 Q4	$13.3M	Buy	628,372 +146,386	+30%	+$3.27M	0.36%	92
2014 Q3	$11.5M	Buy	481,986 +140,744	+41%	+$3.24M	0.34%	92
2014 Q2	$7.88M	Buy	341,242 +180,932	+113%	+$3.99M	0.24%	101
2014 Q1	$3.66M	Buy	+160,310	New	+$3.42M	0.12%	116

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Douglas C. Lane & Associates's NVO Position: Q4 2015 in Review

Douglas C. Lane & Associates reduced its Novo Nordisk (NVO) stake by 4.5% in Q4 2015, selling an estimated $895K and leaving 684,784 shares worth $19.9M. The position accounts for 0.54% of the portfolio, ranked #69.

Douglas C. Lane & Associates first reported a position in NVO in Q1 2014 and has held it in 8 quarters since. 549 funds tracked by Wall St. Rank hold NVO as of Q4 2015.

Douglas C. Lane & Associates held 684,784 shares of Novo Nordisk worth $19.9M as of Q4 2015.
Douglas C. Lane & Associates sold 32,322 Novo Nordisk shares in Q4 2015, an estimated $895K.
Novo Nordisk made up 0.54% of Douglas C. Lane & Associates's portfolio in Q4 2015, its #69 holding.
Douglas C. Lane & Associates first reported a position in Novo Nordisk in Q1 2014 and has held it in 8 quarters since.
549 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2015.

Based on Douglas C. Lane & Associates's 13F filing for Q4 2015, filed 25 Jan 2016.